NewSpring Capital Leads Financing as Kincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies
September 17, 2026
Kincell Bio and Cellipont Bioservices completed their merger to create Kincellis Advanced Therapies, a scaled U.S. contract development and manufacturing organization (CDMO) focused on cell therapies and other advanced modalities. The combined platform spans early development through commercial supply across multiple sites in Florida, North Carolina, and Texas, with the equity financing led by NewSpring Capital and debt support from J.P. Morgan.
- Buyers
- Kincellis Advanced Therapies, NewSpring Capital, Kineticos Life Sciences, HealthQuest Capital, Great Point Partners, J.P. Morgan
- Targets
- Kincell Bio, Cellipont Bioservices
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.